PMC7712032_01
Histopathological findings of the lymph node biopsy performed on case 1 showing (a) R-S cells and scattered small T-lymphoid cells (hematoxylin and eosin, 200x), (b) EBER staining by in situ hybridization (100x), (c) R-S cells and T-lymphoid cells (40%) showing positive Ki-67 immunoreactivity (100x), (d) R-S cells showing weak CD15 immunoreactivity (100x), (e) R-S cells showing weak CD30 immunoreactivity (100x), (f) R-S cells showing positive MUM-1 immunoreactivity (100x), (g) T-lymphoid cells showing positive CD2 immunoreactivity (100x), (h) T-lymphoid cells showing positive CD3 immunoreactivity (100x), (i) T-lymphoid cells showing positive CD5 immunoreactivity (100x), (j) T-lymphoid cells showing weak CD7 immunoreactivity (40x), (k) T-lymphoid cells showing weak CD7 immunoreactivity (100x) and (l) T-lymphoid cells showing positive CD8 > CD4 immunoreactivity (40x).
j_med-2020-0191-fig001.jpg
PMC7712032_01_j_med-2020-0191-fig001.jpg
j_med-2020-0191_fig_001
The second population of small lymphoid cells was characterized by heterotypic nuclei and condensed chromatin. The cells were immunopositive for PD1, CD2, CD3, CD5, CD7, CD8, CD4 (weakly positive), CD8 > CD4, TIA1 and Ki-67 40%+, and immunonegative for GrB, CD10, CD20, CD56 and CXCL-13 (Figure 1).
FCM results showing positive CD2, CD3, CD4, CD5, CD7 and CD8 immunoreactivity in BM cells of case 1.
j_med-2020-0191-fig002.jpg
PMC7712032_01_j_med-2020-0191-fig002.jpg
j_med-2020-0191_fig_002
The results of flow cytometry (FCM) revealed the proportions of lymphocytic and CD3+ cells to be 36.4% and 30.3%, respectively, and BM cells expressed CD2, CD3, CD4dim, CD5, CD7, CD8 and CD4/CD8 (3.9%/61.8% = 0.06) (Figure 2).
PMC7712032_02
Histopathological findings of the BMB performed on case 2 showing moderate infiltration of cells between trabeculae (hematoxylin and eosin, 100x).
j_med-2020-0191-fig003.jpg
PMC7712032_02_j_med-2020-0191-fig003.jpg
j_med-2020-0191_fig_003
Moderate infiltration of large heteromorphic cells was observed between trabeculae (Figure 3).